| scholarly article | Q13442814 |
| P50 | author | Anne Davidson | Q38330484 |
| P2093 | author name string | I Moisini | |
| P2860 | cites work | TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease | Q22254041 |
| Impaired IgA class switching in APRIL-deficient mice | Q24313032 | ||
| BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 | ||
| The role of APRIL and BAFF in lymphocyte activation | Q28249768 | ||
| BAFF, APRIL and their receptors: structure, function and signaling | Q28258238 | ||
| BAFF, APRIL and human B cell disorders | Q28258436 | ||
| Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production | Q28259860 | ||
| BCMA is essential for the survival of long-lived bone marrow plasma cells | Q28587037 | ||
| Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice | Q28587370 | ||
| B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells | Q28590517 | ||
| Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis | Q30484091 | ||
| Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. | Q30491651 | ||
| Prevention of murine antiphospholipid syndrome by BAFF blockade | Q33380975 | ||
| Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus | Q33928629 | ||
| Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. | Q33951524 | ||
| BLyS and APRIL in rheumatoid arthritis | Q34084521 | ||
| Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome | Q34108411 | ||
| Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor | Q34178508 | ||
| Similarities and differences between selective and nonselective BAFF blockade in murine SLE | Q34350295 | ||
| Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome | Q34479625 | ||
| B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome | Q34896699 | ||
| BAFF AND APRIL: a tutorial on B cell survival | Q34994661 | ||
| Autoimmune disease complicating antiviral therapy for hepatitis C virus infection | Q35045126 | ||
| Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice | Q35110335 | ||
| BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. | Q35140484 | ||
| Peripheral B-cell maturation: the intersection of selection and homeostasis | Q35666676 | ||
| Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production | Q35953204 | ||
| BAFF and MyD88 signals promote a lupuslike disease independent of T cells | Q36229560 | ||
| Splenic T zone development is B cell dependent | Q36369671 | ||
| Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival | Q36384731 | ||
| An APRIL to remember: novel TNF ligands as therapeutic targets | Q36394955 | ||
| Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. | Q36402668 | ||
| Identification of proteoglycans as the APRIL-specific binding partners. | Q36403611 | ||
| Updates from B Cell Trials: Efficacy. | Q36465505 | ||
| Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis | Q36537018 | ||
| The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity | Q36622367 | ||
| A genetic lesion that arrests plasma cell homing to the bone marrow | Q36689920 | ||
| APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa | Q36749700 | ||
| Cytokine-producing B lymphocytes-key regulators of immunity | Q36775913 | ||
| B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling | Q36791432 | ||
| TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity | Q36811126 | ||
| Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis | Q36985612 | ||
| Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus | Q36993242 | ||
| B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation | Q37009908 | ||
| TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties | Q37178196 | ||
| BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? | Q37211258 | ||
| B cells as therapeutic targets in autoimmune neurological disorders | Q37278022 | ||
| Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. | Q37347235 | ||
| A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus | Q37378350 | ||
| Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. | Q39844668 | ||
| TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts | Q40066472 | ||
| Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis. | Q40402453 | ||
| Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. | Q40474288 | ||
| Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells | Q41698462 | ||
| Selective activation of TACI by syndecan-2 | Q42193929 | ||
| The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome | Q43050637 | ||
| Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. | Q43868814 | ||
| Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. | Q44223059 | ||
| A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses | Q45302161 | ||
| B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. | Q46001110 | ||
| Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial | Q46353641 | ||
| Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease | Q46495884 | ||
| Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. | Q47365613 | ||
| Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. | Q47368403 | ||
| Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome | Q47739038 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. | Q51833354 | ||
| Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. | Q51966554 | ||
| Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. | Q53519864 | ||
| Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. | Q53547907 | ||
| B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. | Q54707196 | ||
| Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus | Q56903374 | ||
| BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death | Q56964164 | ||
| An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway | Q57230082 | ||
| Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus | Q59031797 | ||
| Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjögren's syndrome | Q73155009 | ||
| A role for BLyS in tissue inflammation? | Q73249032 | ||
| Regulation of the T-independent humoral response by TACI | Q73923479 | ||
| Lymphoid neogenesis in rheumatoid synovitis | Q74147962 | ||
| Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity | Q74433998 | ||
| Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells | Q74460576 | ||
| Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes | Q77488392 | ||
| TACI regulates IgA production by APRIL in collaboration with HSPG | Q79374551 | ||
| IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells | Q79803345 | ||
| Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome | Q80060016 | ||
| Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis | Q80340621 | ||
| BAFF overexpression is associated with autoantibody production in autoimmune diseases | Q80367249 | ||
| Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study | Q80419633 | ||
| TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells | Q80427855 | ||
| Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b | Q81258368 | ||
| Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity | Q81261843 | ||
| BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands | Q81377143 | ||
| IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice | Q81434854 | ||
| Drug-induced systemic lupus erythematosus and TNF-alpha blockers | Q94077789 | ||
| Rituximab in relapsing-remitting multiple sclerosis | Q94701888 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 155-163 | |
| P577 | publication date | 2009-07-30 | |
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | BAFF: a local and systemic target in autoimmune diseases | |
| P478 | volume | 158 |
| Q40439034 | APRIL gene polymorphism and serum sAPRIL levels in children with systemic lupus erythematosus |
| Q33829848 | Angiotensin II synergizes with BAFF to promote atheroprotective regulatory B cells |
| Q41862447 | Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys. |
| Q44295692 | Association analysis of BANK1 gene with psoriasis in Southern Han Chinese |
| Q38708467 | Autoantibodies against BAFF, APRIL or IL21 - an alternative pathogenesis for antibody-deficiencies? |
| Q38961202 | B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. |
| Q64055652 | B cell activation factor (BAFF) induces inflammation in the human fallopian tube leading to tubal pregnancy |
| Q37603296 | B cells as therapeutic targets in SLE. |
| Q38932311 | B cells in chronic obstructive pulmonary disease: moving to center stage. |
| Q38026784 | B-cell depletion in the treatment of lupus nephritis |
| Q35821274 | B-cell-activating factor affects the occurrence of thyroid autoimmunity in chronic hepatitis C patients treated with interferon alpha |
| Q37495356 | BAFF activates Erk1/2 promoting cell proliferation and survival by Ca2+-CaMKII-dependent inhibition of PP2A in normal and neoplastic B-lymphoid cells. |
| Q59304350 | BAFF inhibits autophagy promoting cell proliferation and survival by activating Ca2+-CaMKII-dependent Akt/mTOR signaling pathway in normal and neoplastic B-lymphoid cells |
| Q84074798 | BAFF serum levels in myasthenia gravis: effects of therapy |
| Q36372629 | BCR and co-receptor crosstalk facilitate the positive selection of self-reactive transitional B cells |
| Q37960525 | Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus |
| Q35134860 | Characterization of B cells in muscle-specific kinase antibody myasthenia gravis |
| Q99709099 | Contributions of Major Cell Populations to Sjögren's Syndrome |
| Q36658257 | Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction |
| Q36989837 | Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study |
| Q87034577 | Effect of Xinfeng capsule in the treatment of active rheumatoid arthritis: a randomized controlled trial |
| Q37691074 | Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study |
| Q41705537 | Evaluation of biochemical parameters and local and systemic levels of osteoactive and B-cell stimulatory factors in gestational diabetes in the presence or absence of gingivitis |
| Q33979850 | Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency |
| Q34742821 | Factors supporting intrathecal humoral responses following viral encephalomyelitis. |
| Q36250237 | Follicular dendritic cells in health and disease |
| Q36790778 | From the Large Scale Expression Analysis of Lupus Nephritis to Targeted Molecular Medicine |
| Q53014578 | Gene Therapy for Autoimmune Disease. |
| Q39729327 | IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells |
| Q37873808 | Immunologic similarities between selected autoimmune diseases and peanut allergy: possible new therapeutic approaches |
| Q34937443 | Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer |
| Q94467533 | Increased Ileal Immunoglobulin A Production and Immunoglobulin A-Coated Bacteria in Diarrhea-Predominant Irritable Bowel Syndrome |
| Q48215859 | Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations |
| Q39272758 | Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity |
| Q39132739 | Lentinula edodes-derived polysaccharide enhances systemic and mucosal immunity by spatial modulation of intestinal gene expression in mice |
| Q34434727 | MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts |
| Q35369982 | Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy |
| Q38151163 | Midkine as a regulator of B cell survival in health and disease |
| Q50878352 | Modulation of the immune system for the treatment of glaucoma. |
| Q34044394 | Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice |
| Q47415240 | Neutrophil extracellular traps as a potential source of autoantigen in cocaine-associated autoimmunity |
| Q58616776 | PD-1 immunobiology in systemic lupus erythematosus |
| Q33429051 | Participation of B-cell-activating factor receptors in the pathogenesis of immune thrombocytopenia |
| Q38903921 | Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells |
| Q89729975 | Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells |
| Q40789497 | Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells |
| Q35686885 | Regulation of the B cell receptor repertoire and self-reactivity by BAFF |
| Q34185830 | Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement |
| Q49120393 | Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease |
| Q43940654 | Saliva and serum levels of B-cell activating factors and tumor necrosis factor-α in patients with periodontitis. |
| Q36106681 | Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome |
| Q50438780 | Serum BAFF and APRIL levels in patients with autoimmune hemolytic anemia and their clinical significance |
| Q35452032 | Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease |
| Q40707363 | The BAFFling problem of B cell-activating factor in nonalcoholic fatty liver disease |
| Q92940532 | The Contribution of B Cells in Autoimmune Liver Diseases |
| Q90242330 | The effects of BAFF on T lymphocytes in chronic obstructive pulmonary disease |
| Q33748041 | The function of BAFF on T helper cells in autoimmunity |
| Q35167132 | The plasma concentration of the B cell activating factor is increased in children with acute malaria |
| Q43779090 | Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF. |
| Q38725378 | Transgenic overexpression of BAFF regulates the expression of immune-related genes in zebrafish, Danio rerio |
| Q37912214 | Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? |
| Q58843651 | Trypanosoma cruzi antigen immunization induces a higher B cell survival in BALB/c mice, a susceptible strain, compared to C57BL/6 B lymphocytes, a resistant strain to cardiac autoimmunity |
Search more.